Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government for its inactivated COVID-19 vaccine, VLA2001.
If vaccine development is successful, Valneva will provide the UK government with 60 million doses in the second half of 2021.
The UK government then has options over 40 million doses in 2022 and a further 30 million to 90 million doses, in aggregate, across 2023 to 2025.
Revenue from these options could amount to almost €900 million.
Valneva’s inactivated SARS-CoV-2 vaccine is expected to have a two dose regimen. UK government is also investing up-front in the scale up and development of the vaccine, with the investment being recouped against the vaccine supply under the partnership.
The agreement follows the initial intent to participate in the UK Government’s COVID-19 vaccine response announced in July.